News
17h
Everyday Health on MSNPeople With Weight-Related Chronic Liver Disease Have a New Treatment Option
The U.S. Food and Drug Administration approved the obesity drug Wegovy for people with the chronic liver disease known as ...
In a significant breakthrough for the treatment of liver disease, Novo Nordisk's Wegovy has received U.S. approval for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) in ...
Madrigal Pharmaceuticals’ Rezdiffra has been approved in Europe for the treatment of MASH with moderate to advanced liver ...
Ozempic, chemically known as semaglutide, is now the first approved treatment in Canada for type 2 diabetes and to slow ...
Viking Therapeutics' weight-loss pill trial results underwhelmed, causing a sharp decline in shares. Meanwhile, Novo Nordisk's liver disease approval for Wegovy uplifted its stock. European corporate ...
Health Canada approved Ozempic for type 2 diabetes patients with chronic kidney disease after positive FLOW trial results.
22hon MSN
Why Novo Nordisk Stock Popped Today
Novo Nordisk (NYSE: NVO) stock is up 2.2% through 10:30 a.m. ET on Viking's bad news. Where to invest $1,000 right now? Our ...
Ozempic accidentally became a cultural phenomenon. The drug, first delivered to diabetes patients in 2017, had a huge impact ...
The FDA has granted accelerated approval for Wegovy for the treatment of noncirrhotic MASH with moderate to advanced liver fibrosis in adults.
NEW YORK (AP) — Wall Street is holding near its record heights on Monday, ahead of a week likely to be dominated by updates ...
A group of vaccine-skeptical doctors and mandate opponents is challenging the CDC’s childhood immunization schedule in ...
The AHA’s new 2025 blood pressure guidelines emphasize lifestyle changes, stress management, and medication to help prevent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results